HYDRAP-ES Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hydrap-es, and what generic alternatives are available?
Hydrap-es is a drug marketed by Sandoz and is included in one NDA.
The generic ingredient in HYDRAP-ES is hydralazine hydrochloride; hydrochlorothiazide; reserpine. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide; reserpine profile page.
Summary for HYDRAP-ES
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 71 |
Formulation / Manufacturing: | see details |
DailyMed Link: | HYDRAP-ES at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for HYDRAP-ES
US Patents and Regulatory Information for HYDRAP-ES
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sandoz | HYDRAP-ES | hydralazine hydrochloride; hydrochlorothiazide; reserpine | TABLET;ORAL | 084876-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |